GSK Plc said its blood cancer drug significantly reduced the risk of death when combined with another cancer treatment, ...

(Alliance News) - GSK PLC on Thursday said its Blenrep drug has shown overall survival benefits in patients with relapsed or refractory multiple myeloma, the third most common type of blood cancer.

GSK reported positive results from its phase three ‘DREAMM-7’ trial on Thursday, highlighting a significant overall survival ...

GSK Plc said its blood cancer drug significantly reduced the risk of death when combined with another cancer treatment, ...

GSK plc (GSK, GSK.L), on Thursday, announced positive headline results from a planned interim analysis of the DREAMM-7 head-to-head ...

Q3 2024 Earnings Call Transcript October 30, 2024 GSK plc beats earnings expectations. Reported EPS is $1.29, expectations were $1.23. Operator: Hello, everyone. Welcome to today’s call and webcast.

Blenrep, Depemokimab, Nucala for COPD, Gepotidacin, and our new vaccine to prevent meningitis (MenABCWY).' Sheena Berry, an analyst at Quilter Cheviot, said: 'GSK’s third quarter results for ...

Blenrep, a treatment for cancer, and asthma medicine Depemokimab are among the planned new launches. Nonetheless, shares in the company fell after it cut its outlook for its annual vaccines sales ...